Preclinical Development of a Stabilized RH5 Virus-Like Particle Vaccine that Induces Improved Anti-Malarial Antibodies
Abstract The development of a highly effective vaccine against the pathogenic blood-stage infection of human malaria will require a delivery platform that can induce an antibody response of both maximal quantity and functional quality. One strategy to achieve this includes presenting antigens to the immune system on virus-like particles (VLPs). Here we sought to improve the design and delivery of the blood-stagePlasmodium falciparumreticulocyte-binding protein homolog 5 (RH5) antigen, which is currently in a Phase 2 clinical trial as a full-length soluble protein-in-adjuvant vaccine candidate called RH5.1/Matrix-M™. We identify disordered regions of the full-length RH5 molecule induce non-growth inhibitory antibodies in human vaccinees, and a re-engineered and stabilized immunogen that includes just the alpha-helical core of RH5 induces a qualitatively superior growth-inhibitory antibody response in rats vaccinated with this protein formulated in Matrix-M™ adjuvant. In parallel, bioconjugation of this new immunogen, termed “RH5.2”, to hepatitis B surface antigen VLPs using the “plug-and-display” SpyTag-SpyCatcher platform technology also enabled superior quantitative antibody immunogenicity over soluble antigen/adjuvant in vaccinated mice and rats. These studies identify a new blood-stage malaria vaccine candidate that may improve upon the current leading soluble protein vaccine candidate RH5.1/Matrix-M™. The RH5.2-VLP/Matrix-M™ vaccine candidate is now under evaluation in Phase 1a/b clinical trials..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 10. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2024.01.04.574181 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI04207391X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI04207391X | ||
| 003 | DE-627 | ||
| 005 | 20240111090728.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240106s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2024.01.04.574181 |2 doi | |
| 035 | |a (DE-627)XBI04207391X | ||
| 035 | |a (biorXiv)10.1101/2024.01.04.574181 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a King, Lloyd D. W. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preclinical Development of a Stabilized RH5 Virus-Like Particle Vaccine that Induces Improved Anti-Malarial Antibodies |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The development of a highly effective vaccine against the pathogenic blood-stage infection of human malaria will require a delivery platform that can induce an antibody response of both maximal quantity and functional quality. One strategy to achieve this includes presenting antigens to the immune system on virus-like particles (VLPs). Here we sought to improve the design and delivery of the blood-stagePlasmodium falciparumreticulocyte-binding protein homolog 5 (RH5) antigen, which is currently in a Phase 2 clinical trial as a full-length soluble protein-in-adjuvant vaccine candidate called RH5.1/Matrix-M™. We identify disordered regions of the full-length RH5 molecule induce non-growth inhibitory antibodies in human vaccinees, and a re-engineered and stabilized immunogen that includes just the alpha-helical core of RH5 induces a qualitatively superior growth-inhibitory antibody response in rats vaccinated with this protein formulated in Matrix-M™ adjuvant. In parallel, bioconjugation of this new immunogen, termed “RH5.2”, to hepatitis B surface antigen VLPs using the “plug-and-display” SpyTag-SpyCatcher platform technology also enabled superior quantitative antibody immunogenicity over soluble antigen/adjuvant in vaccinated mice and rats. These studies identify a new blood-stage malaria vaccine candidate that may improve upon the current leading soluble protein vaccine candidate RH5.1/Matrix-M™. The RH5.2-VLP/Matrix-M™ vaccine candidate is now under evaluation in Phase 1a/b clinical trials. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Pulido, David |4 aut | |
| 700 | 1 | |a Barrett, Jordan R. |0 (orcid)0000-0003-0746-1945 |4 aut | |
| 700 | 1 | |a Davies, Hannah |4 aut | |
| 700 | 1 | |a Quinkert, Doris |4 aut | |
| 700 | 1 | |a Lias, Amelia M. |4 aut | |
| 700 | 1 | |a Silk, Sarah E. |4 aut | |
| 700 | 1 | |a Pattinson, David J. |4 aut | |
| 700 | 1 | |a Diouf, Ababacar |4 aut | |
| 700 | 1 | |a Williams, Barnabas G. |4 aut | |
| 700 | 1 | |a McHugh, Kirsty |0 (orcid)0000-0002-5411-7883 |4 aut | |
| 700 | 1 | |a Rodrigues, Ana |4 aut | |
| 700 | 1 | |a Rigby, Cassandra A. |4 aut | |
| 700 | 1 | |a Strazza, Veronica |4 aut | |
| 700 | 1 | |a Suurbaar, Jonathan |4 aut | |
| 700 | 1 | |a Rees-Spear, Chloe |4 aut | |
| 700 | 1 | |a Dabbs, Rebecca A. |4 aut | |
| 700 | 1 | |a Ishizuka, Andrew S. |4 aut | |
| 700 | 1 | |a Zhou, Yu |4 aut | |
| 700 | 1 | |a Gupta, Gaurav |4 aut | |
| 700 | 1 | |a Jin, Jing |4 aut | |
| 700 | 1 | |a Li, Yuanyuan |4 aut | |
| 700 | 1 | |a Carnrot, Cecilia |4 aut | |
| 700 | 1 | |a Minassian, Angela M. |0 (orcid)0000-0001-7832-9824 |4 aut | |
| 700 | 1 | |a Campeotto, Ivan |0 (orcid)0000-0002-0814-619X |4 aut | |
| 700 | 1 | |a Fleishman, Sarel J. |0 (orcid)0000-0003-3177-7560 |4 aut | |
| 700 | 1 | |a Noe, Amy R. |4 aut | |
| 700 | 1 | |a MacGill, Randall S. |4 aut | |
| 700 | 1 | |a King, C. Richter |4 aut | |
| 700 | 1 | |a Birkett, Ashley J. |4 aut | |
| 700 | 1 | |a Soisson, Lorraine A. |4 aut | |
| 700 | 1 | |a Long, Carole A. |4 aut | |
| 700 | 1 | |a Miura, Kazutoyo |4 aut | |
| 700 | 1 | |a Ashfield, Rebecca |4 aut | |
| 700 | 1 | |a Skinner, Katherine |4 aut | |
| 700 | 1 | |a Howarth, Mark |0 (orcid)0000-0001-8870-7147 |4 aut | |
| 700 | 1 | |a Biswas, Sumi |0 (orcid)0000-0001-8507-7282 |4 aut | |
| 700 | 1 | |a Draper, Simon J. |0 (orcid)0000-0002-9415-1357 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 10. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:10 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2024.01.04.574181 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 10 |c 01 | ||